No Signs of Slowdown in NGS Sequencing Market

A couple of recent announcements in the next-generation sequencing (NGS) market got our attention as strong signs that both technology and applications are rapidly diversifying within that arena. It’s continued evidence that the NGS market is not only expanding rapidly,… Read »

Report on ESMO 2018 – Part Two

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma,… Read »

Report on ESMO 2018 – Part One

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings, plus plenty of positive data from a variety of combination therapy… Read »

Artificial Intelligence and Real-time Data Improving Hospital Performance, Reducing Costs

Air traffic control-like, multiple screen “command centers,” are proving to be very effective tools for a small handful of busy hospitals to improve workflow efficiency, reduce wait times, allocate resources, and better orchestrate complex patient care and treatment.  The new… Read »

“All of Us” Achieves Substantial Recruitment Milestone in Record Time

In 2015, the U.S. National Institutes of Health (NIH) announced plans for a major precision medicine initiative. The program is designed to take into account individual differences in lifestyle, environment and biology by gathering health data over time from more than… Read »

A Crowded Field for Migraine Therapies, Where Recently There Were None

Back in March, when we first wrote about migraine drug development, there were no approved therapies addressing the underlying mechanisms of these painful, sometimes chronic, headaches — the most prevalent neurological disorder worldwide. Now, three such drugs have reached the… Read »

DEA Greenlights Epidiolex Launch with Drug Schedule Reclassification

Earlier this year, we wrote that GW Pharmaceuticals was poised to receive the first approval from the U.S. Food and Drug Administration (FDA) for a drug derived from the cannabis plant — Epidiolex (cannabidiol, also known as CBD), a treatment… Read »

First RNAi Drug Hits the Market — At a Very High Price

On August 13, the U.S. Food and Drug Administration (FDA) approved Alnylam’s Onpattro (patisiran), rapidly followed by that product’s approval in Europe three weeks later.  Onpattro, which we previously wrote about, is the first RNAi-based treatment to reach the marketplace…. Read »

Innovations in Electronic Health Records

Increasingly, hospital and health systems have moved from paper charts to electronic health records (EHRs). EHRs offer ways to streamline clinical workflows, reduce medical errors and increase patient safety, and provide stronger support for clinical decision-making. However, linking such records… Read »

Gene Therapy Update Part 2

Last week we wrote about recent news in the field of CRISPR/Cas9 research. But CRISPR is not the only approach to gene editing under development, nor the most advanced.   First Human Gene Editing Data — But Not from CRISPR… Read »

1 2 3 13